Share Price and Basic Stock Data
Last Updated: April 21, 2025, 2:04 pm
| PEG Ratio | 0.00 |
|---|
Competitors of Dishman Carbogen Amcis Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 161 Cr. | 114 | 247/84.3 | 23.3 | 36.5 | 0.00 % | 18.0 % | 15.5 % | 10.0 |
| MPS Pharmaa Ltd | 6.06 Cr. | 3.17 | 4.33/2.75 | 0.80 | 0.00 % | 9.15 % | 34.9 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 46.0 Cr. | 62.0 | 94.9/44.5 | 15.6 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 34.3 Cr. | 23.4 | 29.0/13.1 | 35.0 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
| Industry Average | 17,663.79 Cr | 1,128.72 | 43.89 | 182.59 | 0.34% | 16.00% | 16.30% | 6.24 |
Quarterly Result
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 562.08 | 568.99 | 540.61 | 613.96 | 639.79 | 618.56 | 723.38 | 586.59 | 651.09 | 654.71 | 523.78 | 789.04 | 682.34 |
| Expenses | 452.58 | 547.00 | 452.32 | 535.36 | 525.92 | 567.12 | 601.52 | 525.74 | 609.98 | 592.03 | 494.81 | 641.89 | 542.21 |
| Operating Profit | 109.50 | 21.99 | 88.29 | 78.60 | 113.87 | 51.44 | 121.86 | 60.85 | 41.11 | 62.68 | 28.97 | 147.15 | 140.13 |
| OPM % | 19.48% | 3.86% | 16.33% | 12.80% | 17.80% | 8.32% | 16.85% | 10.37% | 6.31% | 9.57% | 5.53% | 18.65% | 20.54% |
| Other Income | 19.04 | -7.77 | 5.67 | 8.85 | 3.97 | -38.87 | 6.53 | 5.42 | 6.05 | 4.07 | -4.01 | 3.69 | 7.67 |
| Interest | 15.11 | 15.64 | 19.18 | 20.17 | 21.91 | 24.43 | 28.45 | 27.49 | 33.08 | 30.95 | 31.93 | 36.63 | 48.78 |
| Depreciation | 74.95 | 83.88 | 75.08 | 79.57 | 50.33 | 75.74 | 70.45 | 75.04 | 80.37 | 85.00 | 70.59 | 72.09 | 71.97 |
| Profit before tax | 38.48 | -85.30 | -0.30 | -12.29 | 45.60 | -87.60 | 29.49 | -36.26 | -66.29 | -49.20 | -77.56 | 42.12 | 27.05 |
| Tax % | 8.06% | -47.69% | -1,436.67% | -18.23% | -2.98% | -19.27% | 42.35% | 12.80% | -10.05% | 42.11% | 0.01% | 21.44% | 82.88% |
| Net Profit | 35.38 | -44.62 | 4.01 | -10.05 | 46.96 | -70.72 | 17.00 | -40.90 | -59.63 | -69.92 | -77.57 | 33.09 | 4.63 |
| EPS in Rs | 2.26 | -2.85 | 0.26 | -0.64 | 3.00 | -4.51 | 1.08 | -2.61 | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 |
Last Updated: March 3, 2025, 4:43 pm
Below is a detailed analysis of the quarterly data for Dishman Carbogen Amcis Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is 682.34 Cr.. The value appears to be declining and may need further review. It has decreased from 789.04 Cr. (Sep 2024) to 682.34 Cr., marking a decrease of 106.70 Cr..
- For Expenses, as of Dec 2024, the value is 542.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 641.89 Cr. (Sep 2024) to 542.21 Cr., marking a decrease of 99.68 Cr..
- For Operating Profit, as of Dec 2024, the value is 140.13 Cr.. The value appears to be declining and may need further review. It has decreased from 147.15 Cr. (Sep 2024) to 140.13 Cr., marking a decrease of 7.02 Cr..
- For OPM %, as of Dec 2024, the value is 20.54%. The value appears strong and on an upward trend. It has increased from 18.65% (Sep 2024) to 20.54%, marking an increase of 1.89%.
- For Other Income, as of Dec 2024, the value is 7.67 Cr.. The value appears strong and on an upward trend. It has increased from 3.69 Cr. (Sep 2024) to 7.67 Cr., marking an increase of 3.98 Cr..
- For Interest, as of Dec 2024, the value is 48.78 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 36.63 Cr. (Sep 2024) to 48.78 Cr., marking an increase of 12.15 Cr..
- For Depreciation, as of Dec 2024, the value is 71.97 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 72.09 Cr. (Sep 2024) to 71.97 Cr., marking a decrease of 0.12 Cr..
- For Profit before tax, as of Dec 2024, the value is 27.05 Cr.. The value appears to be declining and may need further review. It has decreased from 42.12 Cr. (Sep 2024) to 27.05 Cr., marking a decrease of 15.07 Cr..
- For Tax %, as of Dec 2024, the value is 82.88%. The value appears to be increasing, which may not be favorable. It has increased from 21.44% (Sep 2024) to 82.88%, marking an increase of 61.44%.
- For Net Profit, as of Dec 2024, the value is 4.63 Cr.. The value appears to be declining and may need further review. It has decreased from 33.09 Cr. (Sep 2024) to 4.63 Cr., marking a decrease of 28.46 Cr..
- For EPS in Rs, as of Dec 2024, the value is 0.30. The value appears to be declining and may need further review. It has decreased from 2.11 (Sep 2024) to 0.30, marking a decrease of 1.81.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 6, 2025, 4:27 pm
| Metric | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,031 | 1,714 | 1,695 | 2,059 | 2,044 | 1,912 | 2,141 | 2,413 | 2,616 | 2,650 |
| Expenses | 830 | 1,261 | 1,249 | 1,507 | 1,540 | 1,638 | 1,809 | 2,081 | 2,329 | 2,271 |
| Operating Profit | 201 | 452 | 445 | 552 | 503 | 274 | 331 | 332 | 286 | 379 |
| OPM % | 20% | 26% | 26% | 27% | 25% | 14% | 15% | 14% | 11% | 14% |
| Other Income | 14 | 26 | 46 | 54 | 39 | 16 | 29 | -20 | 22 | 11 |
| Interest | 56 | 49 | 49 | 57 | 62 | 48 | 57 | 86 | 120 | 148 |
| Depreciation | 69 | 214 | 211 | 240 | 283 | 308 | 308 | 281 | 311 | 300 |
| Profit before tax | 91 | 216 | 231 | 309 | 197 | -65 | -4 | -55 | -122 | -58 |
| Tax % | 12% | 33% | 33% | 32% | 20% | 154% | -524% | -45% | 26% | |
| Net Profit | 80 | 145 | 155 | 210 | 159 | -165 | 18 | -30 | -153 | -110 |
| EPS in Rs | 9.58 | 13.03 | 10.10 | -10.53 | 1.15 | -1.90 | -9.79 | -7.00 | ||
| Dividend Payout % | 0% | 0% | 0% | 2% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.90% | 35.48% | -24.29% | -203.77% | 110.91% | -266.67% | -410.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 28.59% | -59.77% | -179.49% | 314.68% | -377.58% | -143.33% |
Dishman Carbogen Amcis Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2023-2024.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 11% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 4% |
| TTM: | 4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 5% |
| 1 Year: | -8% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -1% |
| Last Year: | -3% |
Last Updated: Unknown
Balance Sheet
Last Updated: April 13, 2025, 3:47 pm
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 0.00 | 32 | 32 | 31 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 863 | 4,814 | 5,075 | 5,347 | 5,684 | 5,667 | 5,518 | 5,778 | 5,596 | 5,705 |
| Borrowings | 868 | 950 | 1,095 | 1,042 | 1,357 | 1,589 | 1,830 | 2,209 | 2,313 | 2,507 |
| Other Liabilities | 334 | 811 | 967 | 899 | 1,121 | 1,068 | 1,255 | 1,421 | 1,631 | 1,937 |
| Total Liabilities | 2,081 | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 10,180 |
| Fixed Assets | 1,012 | 4,852 | 5,066 | 5,098 | 5,678 | 5,698 | 5,773 | 6,188 | 6,724 | 7,159 |
| CWIP | 307 | 133 | 151 | 175 | 234 | 486 | 780 | 1,043 | 646 | 580 |
| Investments | 1 | 40 | 196 | 167 | 191 | 172 | 324 | 249 | 102 | 104 |
| Other Assets | 761 | 1,550 | 1,757 | 1,881 | 2,091 | 2,000 | 1,758 | 1,959 | 2,098 | 2,338 |
| Total Assets | 2,081 | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 10,180 |
Below is a detailed analysis of the balance sheet data for Dishman Carbogen Amcis Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 31.00 Cr..
- For Reserves, as of Sep 2024, the value is ₹5,705.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,596.00 Cr. (Mar 2024) to ₹5,705.00 Cr., marking an increase of 109.00 Cr..
- For Borrowings, as of Sep 2024, the value is ₹2,507.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,313.00 Cr. (Mar 2024) to ₹2,507.00 Cr., marking an increase of 194.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹1,937.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,631.00 Cr. (Mar 2024) to ₹1,937.00 Cr., marking an increase of 306.00 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹10,180.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9,571.00 Cr. (Mar 2024) to ₹10,180.00 Cr., marking an increase of 609.00 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹7,159.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,724.00 Cr. (Mar 2024) to ₹7,159.00 Cr., marking an increase of 435.00 Cr..
- For CWIP, as of Sep 2024, the value is ₹580.00 Cr.. The value appears to be declining and may need further review. It has decreased from 646.00 Cr. (Mar 2024) to ₹580.00 Cr., marking a decrease of 66.00 Cr..
- For Investments, as of Sep 2024, the value is ₹104.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Mar 2024) to ₹104.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Sep 2024, the value is ₹2,338.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,098.00 Cr. (Mar 2024) to ₹2,338.00 Cr., marking an increase of 240.00 Cr..
- For Total Assets, as of Sep 2024, the value is ₹10,180.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,571.00 Cr. (Mar 2024) to ₹10,180.00 Cr., marking an increase of 609.00 Cr..
Notably, the Reserves (5,705.00 Cr.) exceed the Borrowings (2,507.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -667.00 | -498.00 | 444.00 | 551.00 | 502.00 | 273.00 | 330.00 | 330.00 | 284.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 61 | 96 | 79 | 103 | 80 | 81 | 89 | 64 |
| Inventory Days | 272 | 473 | 525 | 496 | 462 | 402 | 526 | 568 | 540 |
| Days Payable | 172 | 95 | 201 | 176 | 226 | 132 | 158 | 155 | 149 |
| Cash Conversion Cycle | 160 | 439 | 419 | 399 | 340 | 350 | 449 | 502 | 455 |
| Working Capital Days | 49 | 117 | 129 | 135 | 124 | 135 | 115 | 90 | 100 |
| ROCE % | 5% | 6% | 4% | 0% | 1% | 1% | 0% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HSBC Flexi Cap Fund | 2,377,050 | 0.96 | 33.73 | 2,377,050 | 2025-04-19 17:51:31 | 0% |
| L&T Flexicap Fund - Regular Plan | 2,377,050 | 0.81 | 23.47 | 2,377,050 | 2025-04-19 17:51:31 | 0% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 63,747 | 0.2 | 0.9 | 63,747 | 2025-04-19 17:51:31 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 681 | 0.12 | 0.01 | 681 | 2025-04-19 17:51:31 | 0% |
| Groww Nifty Total Market Index Fund | 149 | 0.01 | 0 | 149 | 2025-04-20 21:55:56 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | -9.79 | -1.90 | 1.15 | -10.53 | 10.10 |
| Diluted EPS (Rs.) | -9.79 | -1.90 | 1.15 | -10.53 | 10.10 |
| Cash EPS (Rs.) | 10.04 | 16.00 | 20.77 | 9.11 | 28.13 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 358.90 | 370.51 | 353.89 | 363.44 | 364.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 358.90 | 370.51 | 353.89 | 363.44 | 364.25 |
| Revenue From Operations / Share (Rs.) | 166.82 | 153.89 | 136.52 | 121.94 | 130.25 |
| PBDIT / Share (Rs.) | 20.07 | 22.96 | 23.90 | 19.95 | 34.55 |
| PBIT / Share (Rs.) | 0.24 | 5.05 | 4.29 | 0.30 | 16.52 |
| PBT / Share (Rs.) | -7.80 | -3.48 | -0.27 | -4.15 | 12.57 |
| Net Profit / Share (Rs.) | -9.79 | -1.90 | 1.15 | -10.53 | 10.10 |
| NP After MI And SOA / Share (Rs.) | -9.79 | -1.90 | 1.15 | -10.53 | 10.10 |
| PBDIT Margin (%) | 12.03 | 14.91 | 17.50 | 16.35 | 26.52 |
| PBIT Margin (%) | 0.14 | 3.28 | 3.13 | 0.25 | 12.68 |
| PBT Margin (%) | -4.67 | -2.26 | -0.19 | -3.40 | 9.64 |
| Net Profit Margin (%) | -5.86 | -1.23 | 0.84 | -8.63 | 7.75 |
| NP After MI And SOA Margin (%) | -5.86 | -1.23 | 0.84 | -8.63 | 7.75 |
| Return on Networth / Equity (%) | -2.72 | -0.51 | 0.32 | -2.89 | 2.77 |
| Return on Capital Employeed (%) | 0.05 | 1.03 | 0.93 | 0.06 | 3.90 |
| Return On Assets (%) | -1.60 | -0.31 | 0.20 | -1.98 | 1.93 |
| Long Term Debt / Equity (X) | 0.04 | 0.18 | 0.13 | 0.08 | 0.04 |
| Total Debt / Equity (X) | 0.34 | 0.31 | 0.25 | 0.18 | 0.16 |
| Asset Turnover Ratio (%) | 0.27 | 0.26 | 0.04 | 0.03 | 0.08 |
| Current Ratio (X) | 0.75 | 1.07 | 1.29 | 1.33 | 1.13 |
| Quick Ratio (X) | 0.40 | 0.61 | 0.84 | 0.91 | 0.76 |
| Inventory Turnover Ratio (X) | 0.71 | 0.86 | 0.29 | 0.22 | 0.47 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 2.03 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.73 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 97.97 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 99.27 |
| Interest Coverage Ratio (X) | 2.62 | 4.20 | 6.60 | 6.57 | 8.75 |
| Interest Coverage Ratio (Post Tax) (X) | -0.22 | 1.21 | 1.57 | -2.00 | 3.56 |
| Enterprise Value (Cr.) | 5245.26 | 3590.64 | 4151.85 | 2477.79 | 1609.53 |
| EV / Net Operating Revenue (X) | 2.01 | 1.49 | 1.94 | 1.30 | 0.78 |
| EV / EBITDA (X) | 16.67 | 9.97 | 11.08 | 7.92 | 2.97 |
| MarketCap / Net Operating Revenue (X) | 1.41 | 0.81 | 1.36 | 0.89 | 0.41 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 97.96 |
| Price / BV (X) | 0.65 | 0.33 | 0.52 | 0.29 | 0.14 |
| Price / Net Operating Revenue (X) | 1.41 | 0.81 | 1.36 | 0.89 | 0.41 |
| EarningsYield | -0.04 | -0.01 | 0.01 | -0.09 | 0.18 |
After reviewing the key financial ratios for Dishman Carbogen Amcis Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 24, the value is -9.79. This value is below the healthy minimum of 5. It has decreased from -1.90 (Mar 23) to -9.79, marking a decrease of 7.89.
- For Diluted EPS (Rs.), as of Mar 24, the value is -9.79. This value is below the healthy minimum of 5. It has decreased from -1.90 (Mar 23) to -9.79, marking a decrease of 7.89.
- For Cash EPS (Rs.), as of Mar 24, the value is 10.04. This value is within the healthy range. It has decreased from 16.00 (Mar 23) to 10.04, marking a decrease of 5.96.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 358.90. It has decreased from 370.51 (Mar 23) to 358.90, marking a decrease of 11.61.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 358.90. It has decreased from 370.51 (Mar 23) to 358.90, marking a decrease of 11.61.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 166.82. It has increased from 153.89 (Mar 23) to 166.82, marking an increase of 12.93.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 20.07. This value is within the healthy range. It has decreased from 22.96 (Mar 23) to 20.07, marking a decrease of 2.89.
- For PBIT / Share (Rs.), as of Mar 24, the value is 0.24. This value is within the healthy range. It has decreased from 5.05 (Mar 23) to 0.24, marking a decrease of 4.81.
- For PBT / Share (Rs.), as of Mar 24, the value is -7.80. This value is below the healthy minimum of 0. It has decreased from -3.48 (Mar 23) to -7.80, marking a decrease of 4.32.
- For Net Profit / Share (Rs.), as of Mar 24, the value is -9.79. This value is below the healthy minimum of 2. It has decreased from -1.90 (Mar 23) to -9.79, marking a decrease of 7.89.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -9.79. This value is below the healthy minimum of 2. It has decreased from -1.90 (Mar 23) to -9.79, marking a decrease of 7.89.
- For PBDIT Margin (%), as of Mar 24, the value is 12.03. This value is within the healthy range. It has decreased from 14.91 (Mar 23) to 12.03, marking a decrease of 2.88.
- For PBIT Margin (%), as of Mar 24, the value is 0.14. This value is below the healthy minimum of 10. It has decreased from 3.28 (Mar 23) to 0.14, marking a decrease of 3.14.
- For PBT Margin (%), as of Mar 24, the value is -4.67. This value is below the healthy minimum of 10. It has decreased from -2.26 (Mar 23) to -4.67, marking a decrease of 2.41.
- For Net Profit Margin (%), as of Mar 24, the value is -5.86. This value is below the healthy minimum of 5. It has decreased from -1.23 (Mar 23) to -5.86, marking a decrease of 4.63.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is -5.86. This value is below the healthy minimum of 8. It has decreased from -1.23 (Mar 23) to -5.86, marking a decrease of 4.63.
- For Return on Networth / Equity (%), as of Mar 24, the value is -2.72. This value is below the healthy minimum of 15. It has decreased from -0.51 (Mar 23) to -2.72, marking a decrease of 2.21.
- For Return on Capital Employeed (%), as of Mar 24, the value is 0.05. This value is below the healthy minimum of 10. It has decreased from 1.03 (Mar 23) to 0.05, marking a decrease of 0.98.
- For Return On Assets (%), as of Mar 24, the value is -1.60. This value is below the healthy minimum of 5. It has decreased from -0.31 (Mar 23) to -1.60, marking a decrease of 1.29.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.18 (Mar 23) to 0.04, marking a decrease of 0.14.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.34. This value is within the healthy range. It has increased from 0.31 (Mar 23) to 0.34, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.27. It has increased from 0.26 (Mar 23) to 0.27, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 24, the value is 0.75. This value is below the healthy minimum of 1.5. It has decreased from 1.07 (Mar 23) to 0.75, marking a decrease of 0.32.
- For Quick Ratio (X), as of Mar 24, the value is 0.40. This value is below the healthy minimum of 1. It has decreased from 0.61 (Mar 23) to 0.40, marking a decrease of 0.21.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.71. This value is below the healthy minimum of 4. It has decreased from 0.86 (Mar 23) to 0.71, marking a decrease of 0.15.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 2.62. This value is below the healthy minimum of 3. It has decreased from 4.20 (Mar 23) to 2.62, marking a decrease of 1.58.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is -0.22. This value is below the healthy minimum of 3. It has decreased from 1.21 (Mar 23) to -0.22, marking a decrease of 1.43.
- For Enterprise Value (Cr.), as of Mar 24, the value is 5,245.26. It has increased from 3,590.64 (Mar 23) to 5,245.26, marking an increase of 1,654.62.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.01. This value is within the healthy range. It has increased from 1.49 (Mar 23) to 2.01, marking an increase of 0.52.
- For EV / EBITDA (X), as of Mar 24, the value is 16.67. This value exceeds the healthy maximum of 15. It has increased from 9.97 (Mar 23) to 16.67, marking an increase of 6.70.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.41. This value is within the healthy range. It has increased from 0.81 (Mar 23) to 1.41, marking an increase of 0.60.
- For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Price / BV (X), as of Mar 24, the value is 0.65. This value is below the healthy minimum of 1. It has increased from 0.33 (Mar 23) to 0.65, marking an increase of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.41. This value is within the healthy range. It has increased from 0.81 (Mar 23) to 1.41, marking an increase of 0.60.
- For EarningsYield, as of Mar 24, the value is -0.04. This value is below the healthy minimum of 5. It has decreased from -0.01 (Mar 23) to -0.04, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dishman Carbogen Amcis Ltd:
- Net Profit Margin: -5.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.05% (Industry Average ROCE: 16%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -2.72% (Industry Average ROE: 16.3%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.22
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.4
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 43.89)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.34
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -5.86%
About the Company - Qualitative Analysis
Dishman Carbogen Amcis Ltd. is a Public Limited Listed company incorporated on 17/07/2007 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L74900GJ2007PLC051338 and registration number is 051338. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 327.35 Cr. and Equity Capital is Rs. 31.36 Cr. for the Year ended 31/03/2024.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Dishman Corporate House, Iscon-Bopal Road, Ahmedabad Gujarat 380058 | dishman@dishmangroup.com www.imdcal.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Janmejay R Vyas | Chairman |
| Mr. Arpit J Vyas | Global Managing Director |
| Mrs. Deohooti J Vyas | Whole Time Director |
| Mr. Rajendra S Shah | Independent Director |
| Mr. Subir Kumar Das | Independent Director |
| Mr. Maitri K Mehta | Independent Director |
FAQ
What is the intrinsic value of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd's intrinsic value (as of 22 April 2025) is ₹118.27 — 43.14% lower the current market price of 208.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,269 Cr. market cap, FY2025-2026 high/low of ₹308/133, reserves of 5,705 Cr, and liabilities of 10,180 Cr.
What is the Market Cap of Dishman Carbogen Amcis Ltd?
The Market Cap of Dishman Carbogen Amcis Ltd is 3,269 Cr..
What is the current Stock Price of Dishman Carbogen Amcis Ltd as on 22 April 2025?
The current stock price of Dishman Carbogen Amcis Ltd as on 22 April 2025 is 208.
What is the High / Low of Dishman Carbogen Amcis Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dishman Carbogen Amcis Ltd stocks is ₹308/133.
What is the Stock P/E of Dishman Carbogen Amcis Ltd?
The Stock P/E of Dishman Carbogen Amcis Ltd is .
What is the Book Value of Dishman Carbogen Amcis Ltd?
The Book Value of Dishman Carbogen Amcis Ltd is 366.
What is the Dividend Yield of Dishman Carbogen Amcis Ltd?
The Dividend Yield of Dishman Carbogen Amcis Ltd is 0.00 %.
What is the ROCE of Dishman Carbogen Amcis Ltd?
The ROCE of Dishman Carbogen Amcis Ltd is 0.02 %.
What is the ROE of Dishman Carbogen Amcis Ltd?
The ROE of Dishman Carbogen Amcis Ltd is 2.64 %.
What is the Face Value of Dishman Carbogen Amcis Ltd?
The Face Value of Dishman Carbogen Amcis Ltd is 2.00.